<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155375</url>
  </required_header>
  <id_info>
    <org_study_id>AMAG-FER-CKD-251</org_study_id>
    <nct_id>NCT01155375</nct_id>
  </id_info>
  <brief_title>A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease</brief_title>
  <official_title>A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of IV ferumoxytol compared with oral iron for the
      treatment of pediatric subjects with chronic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Several factors contributed to significant challenges in enrollment and led the Sponsor to
    discontinue the AMAG-FER-CKD-251 study as designed.
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin changes</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) analysis</measure>
    <description>Maximum concentration (Cmax)
Area under the curve (AUC)
Half-life (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Oral iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) iron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>IV Ferumoxytol</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous fumarate</intervention_name>
    <description>oral iron preparation</description>
    <arm_group_label>Oral iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria include:

          1. Males or females 6 months to &lt;18 years of age

          2. CKD non-dialysis subjects or dialysis dependent subjects who are on peritoneal
             dialysis or stable hemodialysis prior to screening

          3. Has IDA defined as: a) hemoglobin ≤12.0 g/dL and b) with either TSAT ≤40% or ferritin
             &lt;100 ng/mL

          4. Female subjects of childbearing potential who are sexually active must be on an
             effective method of birth control for at least 1 month prior to screening and agree
             to remain on birth control until completion of participation in the study

        Key Exclusion Criteria include:

          1. History of allergy to either oral or intravenous (IV) iron

          2. Hemoglobin ≤7.0 g/dL

          3. Serum ferritin &gt;600 ng/mL

          4. Female subjects who are pregnant or intend to become pregnant, or are breastfeeding,
             are within 3 months postpartum, or have a positive serum pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMAG Pharmaceuticals, Inc.</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 19, 2016</lastchanged_date>
  <firstreceived_date>June 28, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron deficiency anemia</keyword>
  <keyword>Feraheme</keyword>
  <keyword>ferumoxytol</keyword>
  <keyword>CKD</keyword>
  <keyword>pediatric</keyword>
  <keyword>dialysis-dependent</keyword>
  <keyword>non-dialysis dependent</keyword>
  <keyword>The treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferrous fumarate</mesh_term>
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
